Citeline Podcasts Citeline

A new diagnostic technology to screen and triage individuals based on breath.

Scrip’s senior editor Vibha Ravi speaks with Jack Hoppin, CEO and chairman, and John Babich, chief scientific officer, at Ratio Therapeutics, about the company’s radiopharmaceuticals pipeline, investment by BMS, use of AI, trends and developments in radiopharma research like combining ADCs or PARP inhibitors and more.
https://scrip.citeline.com/SC150098/Ratio-Therapeutics-On-BMS-Investment-Radiopharma-RD-Trends-AI-Use

In this Chinese- and English-language episode, guest speaker Treehill Partners co-founder Ali Parshadezah joins Brian Yang and Dexter Yan to discuss updates on the proposed US BIOSECURE Act and US-China biotech movements, including recent M&A activity.
https://scrip.citeline.com/SC150090/China-Biotech-Podcast-BIOSECURE-Updates-GenmabProfound-Deal

Audio roundup of selected biopharma industry content from Scrip over the business week ended 12 April 2024. In this episode: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
https://scrip.citeline.com/SC150097/Quick-Listen-Scrips-Five-MustKnow-Things

Pink Sheet reporter and editors discuss Richard Pazdur’s call for more diverse opinions in FDA advisory committee meeting open public hearings (:36), agency questions about the stakeholders sponsors consult to execute clinical trial diversity plans (20:52), and Stealth BioTherapeutics’ application for the Barth Syndrome candidate elamipretide getting reviewed (32:23).

More On These Topics From The Pink Sheet

Adcomm Open Public Hearings Have Become Too Sponsor-Driven – US FDA's Pazdur: https://pink.citeline.com/PS150077/Adcomm-Open-Public-Hearings-Have-Become-Too-SponsorDriven--US-FDAs-Pazdur

Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations: https://pink.citeline.com/PS150081/Clinical-Trial-Diversity-Requires-Sponsors-Work-With-An-Assortment-Of-Patient-Advocates-Community-Organizations

Stealth’s Elamipretide Gets US FDA Review, But Same Questions Linger: https://pink.citeline.com/PS150070/Stealths-Elamipretide-Gets-US-FDA-Review-But-Same-Questions-Linger

In this episode, In Vivo speaks to 2024 Rising Leader Hanadie Yousef, CEO of Juvena Therapeutics, about her journey, the secretome as a source of therapeutics, longevity medicine and alternatives to GLP-1 inhibitors for obesity.